<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987142</url>
  </required_header>
  <id_info>
    <org_study_id>CX501/TCEB</org_study_id>
    <nct_id>NCT00987142</nct_id>
  </id_info>
  <brief_title>Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa</brief_title>
  <acronym>TCEB</acronym>
  <official_title>A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigenix S.A.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II, comparative, open label, prospective, multicentre clinical trial where each&#xD;
      patient will undergo two procedures; implant of a patch of cultured chimeric skin&#xD;
      (experimental therapy) in a half of the skin lesion and an occlusive non-adherent dressing&#xD;
      (control) in the other half for 12 months of follow-up in two Spanish centres.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reconstruction of interdigital commisures in patients with severe skin syndactyly using&#xD;
      laminar grafts that will be uniformly and systematically taken with an electrical or&#xD;
      compressed air dermatome on an aseptic area and with the same extent and depth in microns in&#xD;
      all patients.&#xD;
&#xD;
      Immediately after the surgical procedure, a patch of cultured chimeric skin (experimental&#xD;
      therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non&#xD;
      - adherent dressing (control) will be implanted in the other half.&#xD;
&#xD;
      Patients will initially be followed up every two days until epithelisation occurs&#xD;
      (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to epithelization</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroblast persistence</measure>
    <time_frame>3, 8 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>EPIDERMOLYSIS BULLOSA</condition>
  <arm_group>
    <arm_group_label>CX501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured chimeric skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non adherent dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Occlusive non adherent dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX501</intervention_name>
    <description>Cultured chimeric skin</description>
    <arm_group_label>CX501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlusive non adherent dressing</intervention_name>
    <description>Application of an occlusive non adherent dressing in the skin donor site</description>
    <arm_group_label>Non adherent dressing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients of both sexes over 28 days of age.&#xD;
&#xD;
          -  Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and&#xD;
             historical criteria with severe skin syndactyly in whom reconstructive surgery is&#xD;
             indicated.&#xD;
&#xD;
          -  Patients whose legal guardians have given written informed consent for participation&#xD;
             in the study before any study procedure is performed.&#xD;
&#xD;
          -  Patients aged ≥ 12 years who have given written informed consent for participation in&#xD;
             the study before any study procedure is performed.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Women of childbearing age not using effective contraceptive methods (oral&#xD;
             contraception)&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Documented or suspected hypersensitivity to any of the therapeutic agents included in&#xD;
             the study, including anaesthetic drugs.&#xD;
&#xD;
          -  Patients with a history of malignant tumor in the past 5 years&#xD;
&#xD;
          -  Patients with a diagnosis of active tuberculosis at the time of recruitment&#xD;
&#xD;
          -  Patients with prior positive markers for any of the following pathogens: hepatitis b&#xD;
             and c, hiv-1 and hiv-2&#xD;
&#xD;
          -  Patients with a history of clinically relevant hepatic, gastrointestinal,&#xD;
             haematological, pulmonary, or neurological disease no directly related to&#xD;
             epidermolysis bullosa.&#xD;
&#xD;
          -  Any other medical condition which, in the investigator´s judgment, might interfere&#xD;
             with optimal participation in the study or involve a significant risk for the patient.&#xD;
&#xD;
          -  Alcoholism, drug addiction, psychiatric disorders, or other factors present in legal&#xD;
             guardians which,in the investigator´s judgment may complicate patient participation in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Mir-Mir</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

